Statements (31)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
biologic medication |
| gptkbp:activeIngredient |
gptkb:adalimumab
|
| gptkbp:approvalYear |
2018
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
L04AB04
|
| gptkbp:biosimilar |
gptkb:Humira
|
| gptkbp:brand |
gptkb:Hyrimoz
|
| gptkbp:countryOfOperation |
gptkb:European_Union
gptkb:United_States |
| gptkbp:form |
solution for injection
|
| gptkbp:genericName |
adalimumab-adaz
|
| https://www.w3.org/2000/01/rdf-schema#label |
Hyrimoz
|
| gptkbp:indication |
gptkb:juvenile_idiopathic_arthritis
gptkb:Crohn's_disease gptkb:psoriatic_arthritis ulcerative colitis rheumatoid arthritis ankylosing spondylitis plaque psoriasis hidradenitis suppurativa |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Sandoz
|
| gptkbp:mechanismOfAction |
TNF inhibitor
|
| gptkbp:pregnancyCategory |
Consult physician
|
| gptkbp:routeOfAdministration |
subcutaneous injection
|
| gptkbp:storage |
2-8°C
|
| gptkbp:target |
gptkb:tumor_necrosis_factor_alpha
|
| gptkbp:bfsParent |
gptkb:adalimumab
|
| gptkbp:bfsLayer |
7
|